Vakkalanka Bhanu K, Rini Brian I
Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA.
Curr Opin Urol. 2008 Sep;18(5):481-7. doi: 10.1097/MOU.0b013e32830a70cf.
A better understanding of renal cell carcinoma biology has led to a new era of targeted therapy in the management of metastatic renal cell carcinoma.
New phase II and phase III clinical data on both Food and Drug Administration approved and investigational targeted agents are now available, widening the choice of therapies in the treatment of metastatic renal cell carcinoma.
We provide a review of the data to facilitate effective evidence-based clinical practice and also aim to give a perspective for future clinical and translational research in renal cell carcinoma.
对肾细胞癌生物学的深入理解开启了转移性肾细胞癌治疗中靶向治疗的新时代。
关于美国食品药品监督管理局批准的和正在研究的靶向药物的新的II期和III期临床数据现已可得，拓宽了转移性肾细胞癌治疗的疗法选择。
我们对这些数据进行综述以促进基于有效证据的临床实践，并且旨在为未来肾细胞癌的临床和转化研究提供一个视角。
